Management Will Host a Conference Call at 4:30 P.M. ET on the Same Day White Bear Lake, Minnesota --( Newsfile Corp. - October 27, 2026 ) - Envoy Medical® Inc. (NASDAQ: COCH) (" Envoy Medical " or the "Company") , a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced it will report its financial results for the third quarter ended September 30, 2026 , on Thursday, November 5, 2026 . Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Third Quarter 2026 Financial Results Conference Call: Date: Thursday, November 5, 2026 Time: 4:30 P.M. ET Live Call: 1-800-267-6316 ( U.S . Toll Free) or 1-203-518-9783 (International) Webcast: https://ir.envoymedical.com/news-events/ir-calendar For interested individuals unable to join the conference call, a replay will be available through November 19, 2026 , by dialing 1-844-512-2921 ( U.S . Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11162715. To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line. About Envoy Medical, Inc. Envoy Medical (NASDAQ: COCH) is a hearing health and neuroprosthetics company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life. Investor Contact: Phil Carlson KCSA Strategic Communications O: 212.896.1233 E: Envoy@kcsa.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/321048 SOURCE Envoy Medical, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.